MedTrace Logo

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

NCT04013672 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-08-28

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to assess the clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma.

Conditions

Interventions

DRUG

Pembrolizumab

200 mg IV every 3 weeks

DRUG

SurVaxM

500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months

DRUG

Sargramostim

100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months

DRUG

Montanide ISA 51

1 ml per dose dosed every two weeks for 4 doses and then every 3 months

Sponsors & Collaborators

  • David Peereboom

    lead OTHER

Principal Investigators

  • David Peereboom, MD · Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-19
Primary Completion
2021-08-16
Completion
2022-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04013672 on ClinicalTrials.gov